Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Halofenate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 6/20 | 1.00 |
| ▸ | SLC22A12 known ✓ | Q96S37 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RHOC | P08134 | 1/20 | 0.39 |
| ▸ | RHOA | P61586 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arhalofenate SCHEMBL31214631 | 1.00 | PPARG (1.00) | PPARGSLC22A12CNR1ALDH1A1HPGD | |
| Arhalofenate SCHEMBL3302781 | 1.00 | PPARG (1.00) | PPARGSLC22A12CNR1ALDH1A1HPGD | |
| SCHEMBL13374125 | 0.93 | PPARG (0.86) | PPARGSLC22A12ALDH1A1KDM4EGAA | |
| SCHEMBL13374105 | 0.90 | PPARG (0.82) | PPARGSLC22A12CNR1ALDH1A1HPGD | |
| SCHEMBL17702737 | 0.90 | PPARG (0.81) | PPARGSLC22A12CNR1ALDH1A1HPGD | |
| SCHEMBL16580158 | 0.90 | PPARG (0.81) | PPARGSLC22A12CNR1ALDH1A1HPGD | |
| SCHEMBL13374126 | 0.89 | PPARG (0.81) | PPARGSLC22A12ALDH1A1KDM4EGAA | |
| SCHEMBL13374112 | 0.89 | PPARG (0.80) | PPARGSLC22A12CNR1ALDH1A1HPGD | |
| SCHEMBL4009385 | 0.89 | PPARG (0.80) | PPARGSLC22A12ALDH1A1HPGDFAAH | |
| SCHEMBL13374107 | 0.88 | PPARG (0.79) | PPARGSLC22A12CNR1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 683 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109908124-A | Utilize the method for hyperuricemia in Halofenate or HALOFENIC ACID and the second uric acid depressant treatment patient with gout | 西玛贝医药公司 | 2019-06-21 | — | — | CN | claimed |
| US-20160075636-A1 | Process for the Preparation of (-)-(4-Chloro-Phenyl)-(3-Trifluoromethyl-Phenoxy)-Acetic Acid 2-Acetylamino-Ethyl Ester | CYMABAY THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | US | claimed |
| US-9233914-B2 | Crystalline solid and amorphous forms of (−)-halofenate and methods related thereto | CYMABAY THERAPEUTICS, INC. (US) | 2016-01-12 | — | — | US | claimed |
| EP-2945926-A1 | DCC MEDIATED COUPLING FOR HALOFENATE MANUFACTURE | Cymabay Therapeutics, Inc. (US) | 2015-11-25 | — | — | EP | claimed |
| US-20150225333-A1 | Crystalline Solid and Amorphous Forms of (-)-Halofenate and Methods Related Thereto | DIATEX, INC. | 2015-08-13 | — | — | US | claimed |
| CN-104602686-A | Method for treating hyperuricemia in patients with gout using halofenate or halofenac and an anti-inflammatory agent | METABOLEX INC | 2015-05-06 | — | — | CN | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8993797-B2 | Crystalline solid and amorphous forms of (−)-halofenate and methods related thereto | CYMABAY THERAPEUTICS, INC. (US) | 2015-03-31 | — | — | US | claimed |
| EP-2836209-A1 | METHOD FOR TREATING HYPERURICEMIA IN PATIENTS WITH GOUT USING HALOFENATE OR HALOFENIC ACID AND AN ANTI-INFLAMMATORY AGENT | Cymabay Therapeutics, Inc. (US) | 2015-02-18 | — | — | EP | claimed |
| CN-104066427-A | Methods of treating hyperuricemia in patients with gout using halofenate or halofenac and a second uric acid lowering agent | METABOLEX INC | 2014-09-24 | — | — | CN | claimed |
| EP-1614418-A1 | use of(-)(3-trihalomethylphenoxy) (4-halophenyl)acetic acid derivatives for treatment of hyperuricaemia | METABOLEX, INC. (US) | 2006-01-11 | — | — | EP | claimed |
| US-20050075396-A1 | Use of (-)(3-trihalomethylphenoxy)(4-halophenyl) acetic acid derivatives for treatment of insulin resistance, Type 2 diabetes and hyperlipidemia | METABOLEX, INC. (US) | 2005-04-07 | — | — | US | claimed |
| US-20030220399-A1 | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia | METABOLEX, INC. | 2003-11-27 | — | — | US | claimed |
| CN-1443575-A | Medicine for curing metabolic syndrome | LIAONING YILIAN NEW MEDICINE I (CN) | 2003-09-24 | — | — | CN | claimed |
| US-6613802-B1 | Composition containing (-) enantiomer of compound in enantiomeric excess of at least 80% relative to (+) enantiomer, which exhibits reduced inhibition of cytochrome P450 2C9 | METABOLEX, INC. | 2003-09-02 | — | — | US | claimed |
| CN-1433766-A | Medicine for treating metabolism syndrome | LIAONING YILIAN NOVEL MEDICINE (CN) | 2003-08-06 | — | — | CN | claimed |
| EP-1183020-A2 | USE OF(-)(3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL)ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDAEMIA AND HYPERURICAEMIA | METABOLEX, INC. (US) | 2002-03-06 | — | — | EP | claimed |
| US-6262118-B1 | THERAPY OF TYPE 2 DIABETES IN A MAMMAL BY ADMINISTERING (-) 4-CHLOROPHENYL-(3-TRIFLUOROMETHYLPHENOXY)ACETIC ACID DERIVATIVE | METABOLEX, INC. | 2001-07-17 | — | — | US | claimed |
| WO-2000074666-A2 | USE OF (-) (3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDAEMIA AND HYPERURICAEMIA | METABOLEX, INC. (US) | 2000-12-14 | — | — | WO | claimed |
| US-4250191-A | ADMINISTERING A PHENOXYACETIC ACID DERIVATIVE | EDWARDS K DAVID | 1981-02-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075636-A1 | Process for the Preparation of (-)-(4-Chloro-Phenyl)-(3-Trifluoromethyl-Phenoxy)-Acetic Acid 2-Acetylamino-Ethyl Ester | PC, ACACA, ACACB | PPARG 136/4885SLC22A12 2169/4885CNR1 3455/4885 |
| US-20150225333-A1 | Crystalline Solid and Amorphous Forms of (-)-Halofenate and Methods Related Thereto | LIPA, SLC5A2, SLC2A2 | PPARG 422/4885SLC22A12 297/4885CNR1 2929/4885 |
| US-20050075396-A1 | Use of (-)(3-trihalomethylphenoxy)(4-halophenyl) acetic acid derivatives for treatment of insulin resistance, Type 2 diabetes and hyperlipidemia | GPR119, LIPC, HACL2 | PPARG 74/4885SLC22A12 739/4885CNR1 1888/4885 |
| US-20030220399-A1 | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia | HACL2, SLC5A2, HCAR2 | PPARG 281/4885SLC22A12 93/4885CNR1 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.